USAntibiotics, LLC received FDA approval for Amoxicillin and Clavulanate Potassium, a significant development for the generic market that shortens the effective "patent cliff" for the blockbuster Augmentin. The clearance is expected to diversify revenue streams for USAntibiotics, LLC while intensifying competition to drive down prices for the oral antibiotic drug class.